Evidence Table 1. ACE Inhibitor - Accepted Articles

Author, Date	Drug Studied CHF Defined Study population	Sample	Followup	Data reported for specific subpop/ comorb	Data may be at patient level for specific subpop/ comorb	Study name
(Pitt B, 1992)	enalapril Systolic dysfunction Both sympt and asympt patients	6797	NR	NR	Black patients Very old (Age 80+) patients Nursing home patients	SOLVD
(Yusuf S, 1992)	enalapril Systolic dysfunction Post MI and reduced LVEF	4228	NR	Diabetic patients	Black patients Female patients	SOLVD
(The SOLVD Investigators, 1991)	enalapril Systolic dysfunction Symptomatic patients	2569	NR	NR	Black patients Diabetic patients	SOLVD
(Moye LA, 1994)	captopril Systolic dysfunction Asymptomatic patients	2231	2 yr	Black patients Female patients Diabetic patients	No subpopulations	SAVE
(Pfeffer MA, 1992)	captopril Systolic dysfunction Post MI and reduced LVEF	2231	NR	NR	Very old (Age 80+) patients Female patients Diabetic patients	SAVE
(Ball SG, 1993)	ramipril CHF unspecified Symptomatic patients	2006	NR	NR	Female patients Diabetic patients	AIRE
(Cleland JG, 1997)	ramipril CHF unspecified Symptomatic patients	2006	NR	NR	No subpopulations	AIRE
(Exner DV, 2000)	enalapril Systolic dysfunction Symptomatic patients	1996	NR	Black patients	NR	SOLVD

Evidence Table 1. ACE Inhibitor-Accepted Articles (continued)

Author, Date	Drug Studied CHF Defined Study population	Sample	Followup	Data reported for specific subpop/ comorb	Data may be at patient level for specific subpop/ comorb	Study name
(Exner DV, 2001)	enalapril Systolic dysfunction Both sympt and asympt patients	1996	NR	Black patients	No subpopulations	SOLVD
(Kober L, 1995)	trandolapril Systolic dysfunction Symptomatic patients	1749	NR	NR	Very old (Age 80+) patients Female patients Diabetic patients	TRACE
(Torp-Pedersen C, 1996)	trandolapril Systolic dysfunction Symptomatic patients	1749	NR	Diabetic patients Renal failure patients	Female patients	TRACE
(Ambrosioni E, 1995)	zofenopril Systolic dysfunction Asymptomatic patients	1556	NR	Diabetic patients	Female patients None	SMILE
(Hall AS, 1997)	ramipril CHF unspecified Symptomatic patients	603	NR	NR	Female patients Diabetic patients	AIRE
(Bulpitt CJ, 1998)	captopril, cilazapril CHF unspecified Symptomatic patients	367	12 wk	NR	Very old (Age 80+) patients Female patients	Cilazapril/Captopril Multicentre Group
(Captopril-Digoxin Multicenter Research Group, 1988)	captopril Systolic dysfunction Symptomatic patients	300	6 mo	NR	Very old (Age 80+) patients Female patients	Captopril-Digoxin Multicenter Research Group
(Swedberg K, 1999)	enalapril Systolic dysfunction Symptomatic patients	253	NR	NR	Female patients	CONSENSUS

Evidence Table 1. ACE Inhibitor - Accepted Articles (continued)

Author, Date	Drug Studied CHF Defined Study population	Sample	Followup	Data reported for specific subpop/ comorb	Data may be at patient level for specific subpop/ comorb	Study name
(Kjekshus J, 1989)	enalapril Systolic dysfunction Symptomatic patients	253	NR	Renal failure patients	Very old (Age 80+) patients Female patients Diabetic patients	CONSENSUS
(*CONSENSUS*, 1987)	enalapril CHF unspecified Symptomatic patients	253	NR	NR	Female patients Diabetic patients	CONSENSUS
(Jerie P, 1997)	spirapril CHF unspecified Symptomatic patients	248	12 wk	NR	Female patients	CASSIS
(Widimsky J, 1995)	spirapril Systolic dysfunction Symptomatic patients	248	12 wk	NR	Female patients Diabetic patients	CASSIS
(van Veldhuisen DJ, 1998)	imidapril Systolic dysfunction Symptomatic patients	244	12 wk	NR	Female patients	
(Brown EJ Jr, 1995)	fosinopril Systolic dysfunction Symptomatic patients	241	24 wk	NR	Black patients Female patients	Fosinopril Heart Failure Study Group
(Gustafsson I, 1999)	trandolapril Systolic dysfunction Symptomatic patients	237	NR	Diabetic patients	Female patients	TRACE
(Pflugfelder PW, 1993)	quinapril Systolic dysfunction Symptomatic patients	224	16 wk	NR	Female patients	

Evidence Table 1. ACE Inhibitor - Accepted Articles (continued)

Author, Date	Drug Studied CHF Defined Study population	Sample	Followup	Data reported for specific subpop/ comorb	Data may be at patient level for specific subpop/ comorb	Study name
(Gundersen T, 1995)	ramipril Systolic dysfunction Symptomatic patients	223	12 wk	NR	Female patients	Ramipril Multicentre Study
(Giles TD, 1990)	lisinopril CHF unspecified Symptomatic patients	193	12 wk	NR	No subpopulations	lisinopril HF group
(Kleber FX, 1992)	captopril CHF unspecified Symptomatic patients	170	NR	NR	Female patients	Munich Mild Heart Failure
(Ghose JC, 1993)	captopril CHF unspecified Symptomatic patients	153	6 mo	Other	Female patients	
(Barabino A, 1991)	captopril CHF unspecified Symptomatic patients	150	NR mo	Nursing home	Very old (Age 80+) patients Nursing home patients	
(Chalmers JP, 1987)	lisinopril CHF unspecified Symptomatic patients	130	12 wk	NR	Black patients Female patients	
(Newman TJ, 1988)	captopril Systolic dysfunction Symptomatic patients	105	NR	NR	Black patients Female patients	Captopril Multicenter Research Group
(Magnani B , 1988)	captopril CHF unspecified Symptomatic patients	94	6 mo	NR	Female patients	

Evidence Table 1. ACE Inhibitor - Accepted Articles (continued)

Author, Date	Drug Studied CHF Defined Study population	Sample	Followup	Data reported for specific subpop/ comorb	Data may be at patient level for specific subpop/ comorb	Study name
(Magnani B, 1986)	captopril CHF unspecified Symptomatic patients	94	6 mo	NR	Female patients	
(Kleber FX, 1987)	captopril CHF unspecified Symptomatic patients	59	NR	NR	NR	
(Keren G, 1994)	captopril Systolic dysfunction Symptomatic patients	50	1 yr	NR	Female patients	
(Pouleur HG, 1993)	enalapril Systolic dysfunction Asymptomatic patients	49	12 mo	NR	Female patients	SOLVD
(Sharpe DN, 1984)	enalapril CHF unspecified Symptomatic patients	36	3 mo	NR	Very old (Age 80+) patients	
(Bussmann WD, 1987)	captopril CHF unspecified Symptomatic patients	23	6 mo	NR	No subpopulations	
(Creager MA, 1985)	enalapril Systolic dysfunction Symptomatic patients	23	12 wk	NR	NR	

Evidence Table 2. Beta-Blockers- Accepted Articles

ID	Drug Studied CHF Defined Study population	Sample	Followup	Data reported for specific subpop/ comorb	Data may be at patient level for specific subpop/ comorb	Study name
(Hjalmarson A, 1999)	metoprolol Systolic dysfunction Symptomatic patients	3991	NR	Female patients Diabetic patients	Black patients	MERIT-HF
(Hjalmarson A, 2000)	metoprolol Systolic dysfunction Symptomatic patients	3991	NR	Female patients Diabetic patients	Black patients	MERIT-HF
(Wedel H, 2001)	metoprolol Systolic dysfunction Symptomatic patients	3991	NR	Black patients Female patients Diabetic patients	Black patients Female patients	MERIT-HF
(Plehn JF, 2000)	bucindolol Systolic dysfunction Symptomatic patients	2708	NR	Black patients	NR	BEST
(The Beta-Blockers Evaluation of Survival Trial Investigators (BEST, 2001)	bucindolol Systolic dysfunction Symptomatic patients	2708	NR	Black patients Female patients Diabetic patients	Black patients Female patients	BEST
(CIBIS II, 1999)	bisoprolol Systolic dysfunction Symptomatic patients	2647	NR	NR	Female patients	CIBIS
(Erdmann E, 2001)	bisoprolol Systolic dysfunction Symptomatic patients	2647	NR	Female patients Diabetic patients Renal failure patients	NR	CIBIS
(Packer M, 2001)	carvedilol Systolic dysfunction Symptomatic patients	2289	NR	Female patients	Female patients	US Carvedilol HF Study
(Packer M , 1996)	carvedilol Systolic dysfunction Symptomatic patients	1094	NR	Female patients	NR	US Carvedilol HF Study
(Yancy CW, 2001)	carcedelol Systolic dysfunction Symptomatic patients	1094	NR	Black patients	No subpopulations	US Carvedilol HF Study

Evidence Table 2. Beta-Blockers- Accepted Articles (continued)

ID	Drug Studied CHF Defined Study population	Sample	Followup	Data reported for specific subpop/ comorb	Data may be at patient level for specific subpop/ comorb	Study name
(Yancy CW, 1997)	carvedilol Systolic dysfunction Symptomatic patients	1025	NR	Black patients	NR	US Carvedilol HF Study
(CIBIS Investigators, 1994)	bisoprolol Systolic dysfunction Symptomatic patients	641	NR	NR	Female patients	CIBIS
(Eicchorn EJ, 2000)	bucindolol Systolic dysfunction Symptomatic patients	627	NR	Black patients	NR	BEST
(The RESOLVD Investigators 2000)	metoprolol Systolic dysfunction Symptomatic patients	426	24 wk	NR	Black patients Female patients Diabetic patients	RESOLVD
(Australia/New Zealand Heart Failure Research Collaborative Group, 1997)	carvedilol Systolic dysfunction Symptomatic patients	415	NR	NR	Female patients	Australia/ NZ HF Research Group
(Waagstein F, 1993)	metoprolol Systolic dysfunction Symptomatic patients	383	NR	NR	Female patients	Metoprolol in Dilated Cardiomyopathy
(Colucci WS, 1996)	carcedilol Systolic dysfunction Symptomatic patients	366	NR	Black patients Other patients Very old (Age 80+) patients	No subpopulations	US Carvedilol HF Study
(Bristow MR, 1996)	carcedilol Systolic dysfunction Symptomatic patients	345	NR	NR	Black patients Very old (Age 80+) patients	Mocha investigation
(Packer M, 1996)	carvedilol Systolic dysfunction Symptomatic patients	278	6 mo	Female patients	Female patients	PRECISE
(Herlitz J, 1997)	metoprolol CHF unspecified Post MI and reduced LVEF	262	NR	NR	Female patients Diabetic patients	Goteborg Metoprolol Trial

Evidence Table 2. Beta-Blockers- Accepted Articles (continued)

ID	Drug Studied CHF Defined Study population	Sample	Followup	Data reported for specific subpop/ comorb	Data may be at patient level for specific subpop/ comorb	Study name
(Cice G, 2000)	carvedilol Systolic dysfunction Symptomatic patients	168	6 mo	NR	Female patients	
(Bristow MR, 1994)	bucindolol Systolic dysfunction Symptomatic patients	139	12 wk	NR	Female patients	
(Witchitz S, 2000)	celiprolol Systolic dysfunction Symptomatic patients	132	1 yr	NR	Female patients	Celicard
(Cohn JN, 1997)	carvedilol Systolic Dysfunction Symptomatic patients	131	6 mo	NR	Black patients Very old (Age 80+) patients Female patients	US Carvedilol HF Study
(Doughty RN, 2000)	carvedilol Systolic dysfunction Symptomatic patients	119	6 mo	NR	Female patients None	Australia/ NZ HF Research Group
(Krum H, 1995)	carvedilol Systolic dysfunction Symptomatic patients	56	NR	NR	Female patients	
(Genth-Zotz S, 2000)	metoprolol Systolic dysfunction Symptomatic patients	52	6 mo	NR	Female patients	MIC
(Anderson JL, 1985)	metoprolol Systolic dysfunction Symptomatic patients	50	NR	NR	Female patients	
(Fisher ML, 1994)	metoprolol Systolic dysfunction Symptomatic patients	50	6 mo	NR	Female patients Diabetic patients	
(Woodley SL, 1991)	bucindolol Systolic dysfunction Symptomatic patients	49	12 wk	NR	Very old (Age 80+) patients	
(Andersson B, 1994)	metoprolol Systolic dysfunction Symptomatic patients	41	6 mo	NR	Very old (Age 80+) patients	

Evidence Table 2. Beta-Blockers- Accepted Articles (continued)

ID	Drug Studied CHF Defined Study population	Sample	Followup	Data reported for specific subpop/ comorb	Data may be at patient level for specific subpop/ comorb	Study name
(Gilbert EM, 1990)	bucindolol Systolic dysfunction Symptomatic patients	24	3 mo	NR	Female patients	
(Eichhorn EJ, 1994)	metaprolol Systolic dysfunction Symptomatic patients	24	3 mo	NR	Black patients	
(Wisenbaugh T, 1993)	nebivolol Systolic dysfunction Symptomatic patients	24	3 mo	NR	Very old (Age 80+) patients	
(Cucchini F, 1988)	metoprolol Systolic dysfunction Symptomatic patients	20	6 mo	NR	Female patients	

Evidence Table 3. ACE Inhibitor Studies Contributing to the Meta-Analysis

Study Name	Author Date Add'l Articles	Mean Treatment Duration	Patient Level Data	ARM #	N	Drug
AIRE AIRE Study Investigators, 1993 ID #00098	Hall, 1991 Cleland, 1997 Hall, 1997 Spargias, 1998	15 months		1	982	placebo
				2	1004	ramipril
CONSENSUS CONSENSUS Trial Study Group, 1987 ID #00128	Swedberg, 1988 Kjekshus, 1989 Eriksson, 1990 Swedberg, 1990 Ljungman, 1992 Swedberg, 1999	188 days	X	1	126	placebo
				2	127	enalapril
SAVE Pfeffer, 1992 ID #00101	Moyé, 1994 Rutherford, 1994 Hager, 1998	42 months		1	1112	placebo
				2	1113	captopril
SMILE Ambrosioni, 1995 ID #00065	Borghi, 1996 Ambrosioni, 1994 Boghi, 1999	6 weeks		1	784	placebo
				2	772	zofenopril

Evidence Table 3. ACE Inhibitor Studies Contributing to the Meta-Analysis (continued)

Study Name	Author Date Add'l Articles	Mean Treatment Duration	Patient Level Data	ARM #	N	Drug
SOLVD-prevention Yusuf, 1992 ID #00072	The SOLVD Invesigators, 1990 The SOLVD Investigators, 1991 Hood, 1991 Pitt, 1992 Konstam, 1992 Bangdiwala, 1992 Johnstone, 1992	37 months	X	1	2117	placebo
				2	2111	enalapril
SOLVD-treatment Yusuf, 1991 ID #00075	Pouleur, 1992 Pouleur, 1993 Rogers, 1994 Benedict, 1996 Konstam, 1996 Kostis, 1996 Shindler, 1996 Dries, 1999 Knight, 1999 Exner, 2000 Exner, 2001 Bourassa, 1993	41 months	X	1	1283	placebo
				2	1284	enalapril
TRACE Kober, 1995 ID #00094	Kober, 1996 Torp-Pedersen, 1996 Gustafsson, 1999	varied	X	1	873	placebo
				2	876	trandolapril

Evidence Table 4. Beta-Blocker Studies Contributing to the Meta-Analysis

Study Name	Author Date Add'l Articles	Mean Treatment Duration	Patient Level Data	ARM #	N	Drug
BEST The Beta-Blocker Evaluation of Survival Trial Investigators, 2001 ID #00439	Plehn, 2000 Eichhorn, 2000 The BEST Steering Cmte., 1995	2 years		1	1354	placebo
				2	1354	bucindolol
CIBIS CIBIS Investigators, 1999 ID #0006	CIBIS Investigators and Cmtes., 1994 Pousset, 1996 Copie, 1996 Lechat, 1997 Funck-Brentano, 2000 Erdmann, 2001	1.3 years		1	1148	placebo
				2	1137	bisoprolol
COPERNICUS Packer, 2001 ID #00441		10.4 months	X	1	1133	placebo
				2	1156	carvedilol
MERIT-HF Hjalmarson, 1999 ID #0007	The Int'l Steering Cmte. On Behalf of the MERIT-HF Study Group, 1997 Goldstein, 1999 Mylona, 1999 Fagerberg, 2000 Hjalmarson, 2000 Wedel, 2001 Ghali, 2002	1 year	X	1	2001	placebo
				2	1990	metoprolol
US Carvedilol Study Packer, 1996 ID #0005	Yancy, 1997 Colucci, 1996 Yancy, 2001	6.5 months		1	398	placebo
				2	696	carvedilol